Some people with celiac disease have atypical presentations—such as negative blood tests or mild symptoms—that make diagnosis difficult and require input from multiple specialists to manage effectively. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine the prevalence, diagnostic criteria, and clinical outcomes of seronegative and potential celiac disease across diverse populations.
A systematic review and meta-analysis of 30+ studies defining and diagnosing seronegative, potential, and slow-responsive celiac disease using standardized biopsy and serology criteria, reporting pooled prevalence, misdiagnosis rates, and long-term complication risks.
A prospective cohort could track whether individuals with seronegative or potential celiac disease progress to classic villous atrophy over time.
A prospective cohort of 500 individuals diagnosed with seronegative or potential celiac disease (positive HLA, positive tTG-IgA negative, normal biopsy) followed for 5 years with annual serology, symptom assessment, and repeat biopsy to determine progression rate to classic celiac disease.
A cross-sectional study could compare clinical features, biopsy findings, and symptom burden across seronegative, potential, and classic celiac disease groups.
A cross-sectional analysis of 300 patients with biopsy-confirmed celiac disease, stratified into seronegative (tTG-IgA negative), potential (positive serology, normal biopsy), and classic (positive serology, villous atrophy) groups, comparing symptom scores, HLA types, and histologic features.
A case-control study could identify biomarkers or genetic variants distinguishing seronegative celiac disease from classic forms.
A case-control study comparing 100 patients with seronegative celiac disease to 100 with classic celiac disease, matched for HLA and age, analyzing serum cytokines, T cell receptor repertoires, and gut microbiome profiles to identify distinguishing features.
An expert opinion can describe clinical patterns and management recommendations for atypical celiac phenotypes without empirical validation.
A narrative review summarizing case reports and expert consensus on managing seronegative and potential celiac disease.